ALK and neoplasm: Crizotinib has made significant progress in treating NSCLC with ALK-rearrangement, but with its extensive use, tumor cells develop drug resistance and become less and less sensitive to the treatment (Dagogo-Jack and Shaw, 2016; Nakagawa et al., 2020).